Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 08:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Participate at November Investor Conferences

SAN CARLOS, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
November 06, 2018 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel...
November 06, 2018 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully treated with a prior PD-1 blocking antibody Median Duration of Response (DOR) of 6.4...
October 30, 2018 08:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018

SAN CARLOS, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
October 29, 2018 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018

SAN CARLOS, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
October 18, 2018 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe

SAN CARLOS, Calif. and GOSSELIES, Belgium , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on...
October 17, 2018 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

Offering Includes Exercise in Full of the Underwriter’s Option to Purchase an Additional 3.3 Million Shares of Common Stock SAN CARLOS, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Iovance...
October 12, 2018 07:45 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock

SAN CARLOS, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on...
October 11, 2018 16:05 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

SAN CARLOS, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on...
October 11, 2018 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program

—FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK...